研究单位：[1]Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.[2]The 307 Hospital of People's Liberation Army,Beijing,Beijing,China,100071[3]Beijing Luhe Hospital Capital Medical University,Beijing,Beijing,China,101100[4]Sun Yat-Sen University Cancer Hospital,Guangzhou,Guangdong,China,510600[5]The Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei,China,050010[6]Affiliated Hospital of Hebei University,Baoding,Heibei,China,071000[7]Zhengzhou Central Hospital,Zhengzhou,Henan,China,450007[8]The First Affiliated Hospita of Zhengzhou University,Zhengzhou,Henan,China,450052[9]Weihai Municipal Hospital,Weihai,Shandong,China,264200[10]Tianjin Medical University Cancer Institute &Hospital,Tianjing,Tianjing,China,300060[11]The Second Affiliated Hospital of Soochow University,Suzhou,Zhejiang,China,215000
研究目的：
The purpose of this study is to evaluate the pharmacokinetic of the experimental drug 304 injection compared with rituximab injection in patients with CD20 positive B-cell non-Hodgkin lymphoma who had previously achieved CR/CRu status but had not deteriorated or relapsed. While to assess the safety and efficacy of the experimental drug 304 injection compared with rituximab injection.
